Understanding the Persistence of Immunity After MenC Vaccines

Completed

• Conditions: Healthy
• Interventions: Procedure: Venepuncture

• Registration Number: NCT01126996
• Lead Sponsor: University of Oxford

Brief Summary

Neisseria meningitidis occurs worldwide as endemic disease1 and is a major cause of invasive infections such as meningitis and septicaemia. Three protein-polysaccharide conjugate serogroup C meningococcal (MenC) vaccines were developed in the late 1990's and an accelerated programme of clinical trials in the UK led to licensure of these MenC vaccines in 1999 and these vaccines were introduced into the routine infant immunisation schedule at 2, 3 and 4 months. However, children who were aged 1-18 years in 2000 only received a single dose of a MenC conjugate vaccine during the mass immunisation campaign.

Previous studies have demonstrated rapid waning of MenC specific antibody concentrations and serum bactericidal antibody (SBA) titres following immunisation in young children. A cross-sectional review on rates of sero-protection against MenC disease in the UK has demonstrated that the majority of children who were immunised with a single dose of a MenC conjugate vaccine between the ages of 1-10 did not have protective titres of MenC SBA 7 years after the immunisation campaign. As this cohort of children reaches adolescence there is a risk of increased transmission of the organism and a resurgence of meningococcal disease in children who do not have protective levels of antibody. There is thus a need to conduct a study evaluating the changes in MenC SBA titres over time in children who received a single dose of a MenC vaccine in early childhood which is the main objective of this study.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-05-18
• Study First Submitted QC: 2010-05-19
• Study First Posted: 2010-05-20
• Study Start: 2010-06
• Primary Completion: 2010-11
• Study Completion: 2010-11
• Status Verified: 2013-05
• Last Update Submitted: 2013-05-07
• Last Update Posted: 2013-05-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

• Participant whose parent is willing and able to give informed consent for participation in the study.
• Participant who gives assent for participation in the study.
• Male or Female, aged 11 to 13 years.
• Known to be free from medical problems as determined by a medical history and clinical assessment
• Participated in the University of Oxford clinical trial: U01-Td5I-303/ C01.183

Exclusion Criteria

• History of invasive meningococcal C disease
• Any vaccination against MenC disease with the exception of a single dose in 2000 during the nationwide MenC immunisation campaign
• Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection.
• Major congenital defects or serious chronic illness

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
MenC vaccinated healthy children	Venepuncture	Children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.

Primary Outcome Measures

Name	Time	Method
Percentage of participants with rSBA titres >1:8 (correlate of protection)	6 months

Secondary Outcome Measures

Name	Time	Method
MenC rSBA GMTs at all time points when sera is available after receiving a dose of MenC vaccine	6 months
Percentage of children at each time point with MenC SBA titres >1:8	6 months

Trial Locations

Locations (1)

Oxford Vaccine Group, University of Oxford; 🇬🇧 Oxford, United Kingdom